Biomarkers in Drug Design
Technology advancements in the molecular characterization of cancers have assisted
researchers to identify an increasing number of key molecular drivers
of cancer progression. These drug discoveries have led to multiple novel
anticancer therapeutics, and clinical advantage in selected patient populations. Despite this, the identification of clinically relevant predictive biomarkers of
response continues to lag behind. In this review, we discuss strategies
for the molecular characterization of cancers and the importance of
biomarkers for the development of novel antitumor therapeutics.
The discovery and evaluation of any novel biomarkers will ideally be specialised to Clinical Laboratory Improvement Amendments (CLIA) and Good Clinical Laboratory Practice
(GCLP) standards, so as to ensure accuracy and reproducibility of
laboratory procedures. Predictive biomarkers indicate the likelihood of
response to a specific antitumor therapy.
Such assays should be scientifically sound, Predictive biomarkers
include both tumor-specific and surrogate biomarkers, and are crucial to
accelerating the drug development process
- Dose-Selection Biomarkers
- Biomarker Discovery for Immuno-Oncology Agents
- Biomarkers in Drug Design & Clinical Trial
- Biomarkers of Toxicity & Pharmacology
- Biomarkers of Efficacy
Submit abstract related to above track in link given below: https://drugformulation.pharmaceuticalconferences.com/abstract-submission.php
No comments:
Post a Comment